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When Edward Derrick named the illness he described in 
1937 as Q (query) fever – ‘until fuller knowledge should 
allow a better name’ [cited in 1] – little did he know how 
well the name fits. Some 75 years later, the illness still 
deserves the name as, in spite of major advances in 
knowledge about the causative bacterium, reservoirs, 
routes of transmission and the clinical manifestations 
of the disease, many queries continue to puzzle clini-
cians, microbiologists, public health experts as well as 
veterinarians. Q fever is a worldwide zoonosis caused 
by  the  intracellular  bacterium  Coxiella  burnetii.  The 
most common clinical presentation is an influenza-like 
illness with varying degrees of pneumonia and hepati-
tis [1]. Acute disease is usually self-limiting. However, 
chronic  presentations,  most  often  endocarditis,  are 
life-threatening.  Infections  in  pregnancy  may  lead  to 
spontaneous abortions or premature delivery, even if 
the infected pregnant woman herself remains asymp-
tomatic [2].
In Europe, the number of reported cases is low and is 
in contrast to results of seroprevalence studies, which 
suggest that between 2% and 14 % of the general pop-
ulation have been previously infected by C. burnetii [3]. 
This discrepancy can be explained by the large propor-
tion of subclinical cases, estimated be about 50%. Also, 
the diagnosis of symptomatic cases is often missed as 
symptoms are non-specific. Laboratory confirmation is 
essential for diagnosis, but is often not sought due to 
low awareness of Q fever among patients and practi-
tioners  outside  high-incidence  areas.  Nevertheless, 
Q  fever  outbreaks  are  regularly  reported  throughout 
Europe  as  well  as  in  other  parts  of  the  world.  Most 
often the source is infected livestock and there are a 
limited number of cases in the vicinity of the affected 
farms.  However,  from  2007  to  2009,  an  outbreak  of 
unprecedented  scale  occurred  in  the  Netherlands, 
involving  3,523  notified  human  cases  [4].  The  Dutch 
health  authorities  faced  many  challenges  regarding 
the identification and control of the source of contami-
nation, the risk for pregnant women and other groups 
likely to develop chronic Q fever, the strategies to be 
used for diagnosis, follow-up and treatment regimens 
of acute and chronic Q fever, and the safety of blood 
transfusion and organ transplantation. Consequently, 
the outbreak sparked a large number of research stud-
ies to address these questions. The outbreak setting 
created the opportunity to study several issues diffi-
cult to address in a low-incidence setting.
In  2010,  given  the  increase  in  the  number  of  cases 
in  the  Netherlands,  a  number  of  questions  arose, 
related to the safety of blood transfusions, the need 
to strengthen surveillance for new cases, the impact 
on health of chronic Q fever and the impact on health 
for  people  in  risk  groups,  such  as  pregnant  women. 
These  issues  were  tackled  in  a  risk  assessment  car-
ried out by the European Centre for Disease Prevention 
and Control (ECDC) [3], at the request of the European 
Commission. The ECDC assessed whether an evidence-
based approach, comparable to the methodology used 
in  clinical  medicine,  was  appropriate  for  giving  pub-
lic  health  advice  on  Q  fever  control  strategies  under 
the  time  constraints  of  an  outbreak.  In  this  issue  of 
Eurosurveillance, Forland et al. present a summary of 
their findings [5]. The most striking finding was the lack 
of scientific evidence for the screening and treatment 
regimens for Q fever in pregnant women. Although a 
retrospective hospital-based study from France and a 
Canadian study emphasise that C. burnetti is a poten-
tial threat to pregnant women, the risk is difficult to 
quantify [6,7]. The retrospective design and selection 
bias of these studies may have led to overestimation 
of the risk.
The risk of acute Q fever patients developing chronic 
Q fever was estimated to be 2% [3]. Both symptomatic 
and asymptomatic infected patients with previous car-
diac  valve  pathology,  aneurysms  or  vascular  grafts, 
with  malignancies  or  who  are  immunocompromised 
are most at risk for developing chronic Q fever. On the 
basis  of  the  findings  of  observational  studies,  ECDC 
recommended to consider targeted case-finding among 
these risk groups and long-term follow-up of acute and 
chronic cases. However, the need to initiate prospec-
tive cohort studies and trials with control groups was 
emphasised, to obtain more robust evidence on how to 
diagnose and treat acute and chronic disease.3 www.eurosurveillance.org
Because of the theoretical possibility that C. burnetii 
can  be  transmitted  through  blood  transfusion,  ECDC 
recommended that active screening of blood and tissue 
products  be  considered,  although  only  a  few  blood-
borne infections have been clearly documented.
The  inhalation  of  contaminated  aerosols  originating 
from the faeces and birth products of infected animals, 
most often cattle, sheep and goats, is the main route 
of transmission in humans. In the literature, estimates 
of the distance infectious particles can spread by air 
range from 400 m to 40 km. The ECDC risk assessment 
team concluded that the most sound data were from a 
Dutch  study  using  a  geographic  information  system, 
which demonstrated that the highest risk of infection 
was within a radius of 5 km from the source [8].
Since the ECDC risk assessment, results of the large 
portfolio of ongoing multidisciplinary research in the 
Netherlands are gradually becoming available and con-
tribute new insights and evidence. In this issue, three 
papers present recent findings.
Munster et al. examine the evidence base for routine 
C. burnetii screening among pregnant women in high-
risk  areas  for  Q  fever  [9].  A  recent  population-based 
study in the Dutch outbreak area showed no evidence 
of adverse pregnancy outcome among women who had 
antibodies to C. burnetii during early pregnancy [10]. 
On the basis of this study and because of the poten-
tial  biases  in  earlier  retrospective  studies  reporting 
adverse  pregnancy  outcomes,  the  authors  judged 
that there still is much uncertainty about the conse-
quences of untreated C. burnetii infection during preg-
nancy. There is also no consensus about the screening 
method or treatment. Therefore, they conclude that at 
this stage, there is no evidence on the effectiveness 
of  a  C.  burnetii-screening  programme  in  the  present 
Dutch setting.
Van  der  Hoek  et  al.  describe  how,  in  the  aftermath 
of the outbreak in the Netherlands, the priorities are 
shifting  from  detection  and  management  of  acute 
cases and control of transmission to the follow-up of 
acute Q fever patients, screening of groups at risk for 
chronic  Q  fever,  screening  of  blood  and  tissue,  and 
human  vaccination  [11].  Although  there  seems  to  be 
an international consensus on the groups most at risk 
for chronic Q fever, the optimal follow-up strategy of 
acute Q fever patients for the early detection and treat-
ment of chronic Q fever and the strategy for screening 
of people in risk groups for chronic Q fever are points 
of controversy. There is an ongoing debate about the 
validity of serological profiles as predictors of chronic 
Q  fever,  which  serological  cut-off  values  should  be 
used, the exact timing and frequency of examinations 
and  serological  follow-up,  and  the  duration  of  treat-
ment [12-16]. The wide variation in serological and PCR 
results during the follow-up of patients with acute Q 
fever implies that the diagnosis of chronic Q fever must 
be based primarily on clinical grounds [15,17]. Van der 
Hoek proposes different serological follow-up strate-
gies for patients with and without known risk factors 
for chronic Q fever [15].
Another  article  by  van  de  Hoek  et  al.  in  this  isssue 
sheds  light  on  the  problem  of  under-diagnosis  and 
under-reporting [18]. The authors estimate that only 7.9 
% of incident infections of C. burnetii that occurred in 
the affected area of the Netherlands were notified, and 
that the 3,522 acute Q fever cases that were notified in 
the country from 2007 to 2009 correspond to more than 
44,000 infections in the same period. The proportion 
of under-diagnosed and under-reported cases is likely 
to vary by region and is expected to be even higher in 
low-incidence areas because of a lack of awareness of 
patients and physicians. These high numbers of undi-
agnosed infections constitute an additional challenge 
for the detection of chronic Q fever.
Adoption of an evidence-based approach is challenging 
in infectious disease epidemiology, especially during 
an outbreak. Forland et al. point out that in many situ-
ations,  observational  studies,  often  retrospective,  or 
natural experiments are the only studies available [5]. 
Such studies provide evidence at the lower level of the 
evidence hierarchy in the Grading of Recommendations 
Assessment,  Development  and  Evaluation  (GRADE) 
system [19]. However, such studies can still be of good 
quality and yield important information. Clearly stat-
ing the strengths and limitations of such studies not 
only enables the best available evidence to be used for 
preliminary recommendations, but also ensures trans-
parency regarding uncertainties and allows knowledge 
gaps and priorities for further research to be clearly 
identified. The evidence base for public health policy 
and  strategies  should  be  continuously  reassessed, 
whenever new evidence is made available through new 
studies.
An evidence-based approach and continuous updates 
are  time-  and  resource-consuming.  However,  con-
sidering  the  consequences  for  health,  the  enormous 
resources that are often needed for the implementa-
tion of the selected strategies and the resulting higher 
quality of public health advice, it is beyond doubt that 
the investment is worth it.
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With  reference  to  the  Q  fever  outbreak  in  the 
Netherlands  in  2009–10,  we  tested  if  an  evidence-
based approach, comparable to the methodology used 
in clinical medicine, was appropriate for giving public 
health advice under time constrains. According to the 
principles of evidence-based methodologies, articles 
were retrieved from bibliographic databases and cat-
egorised  by  type  and  size,  outcome,  strengths  and 
limitations. The risk assessment was conducted in two 
months and involved six staff members. We retrieved 
and  read  559  abstracts  and  selected  approximately 
150  full  text  articles.  The  most  striking  finding  was 
the lack of sound scientific evidence behind standard 
treatment regimes for Q fever in pregnancy. Difficulties 
in  applying  existing  evidence  rating  systems  and  in 
expressing  uncertainties  were  identified  as  prob-
lems during the process. By systematically assessing 
the evidence on several questions about Q fever, we 
were able to draw new conclusions and specify earlier 
statements. We found it difficult to grade the mostly 
observational studies with the known evidence-based 
grading systems. There is need to develop new meth-
ods for grading evidence from different sources in the 
field of public health. We conclude that an evidence-
based approach is feasible for providing a risk assess-
ment within two to three months. 
Introduction
The  European  Centre  for  Disease  Prevention  and 
Control  (ECDC)  may  be  requested  by  the  European 
Commission, the Member States of the European Union 
(EU), third countries and international organisations to 
provide scientific or technical assistance in any field 
within its mandate. Regarding the Q fever outbreak in 
the Netherlands in 2009 and 2010 [1], ECDC was asked 
by  the  European  Commission  to  assess  the  follow-
ing questions: (i) What is the risk and safety of blood 
transfusions, especially from donors who are asymp-
tomatic or still in the incubation phase of the disease? 
(ii) What is known on the impact on health of chronic 
Q fever disease? (iii) What is the impact on health for 
risk groups like pregnant women? (iv) Is it advisable to 
strengthen the surveillance of new cases?
After  a  short-term  risk  assessment  had  been  con-
ducted  within  a  few  days,  we  tested  if  an  evidence-
based approach, comparable to the methodology used 
in clinical medicine, was appropriate for giving more 
in-depth public health advice on Q fever to policy mak-
ers  and  public  health  practitioners.  Evidence-based 
methodologies are increasingly discussed and applied 
in public health practice and health promotion. There 
is  a  growing  consensus  that  scientific  and  technical 
advice in the field of public health should rely on evi-
dence-based science and technology and should aim 
to support evidence-based decision making [2]. During 
this  process,  we  addressed  two  questions:  Does  an 
evidence-based  approach  work  when  advice  has  to 
be given in an outbreak situation, i.e. under time con-
straints? And if so, does change the conclusions com-
pared with more traditional, expert-based approaches?
In this paper we summarise the risk assessment and 
discuss our experiences with applying evidence-based 
methodology in its production.
Background
Q fever is a zoonotic disease caused by the intracel-
lular bacterium Coxiella burnetii. A wide range of wild 
and  domestic  animals  (including  arthropods,  birds, 
rodents,  cats,  and  livestock)  serve  as  a  natural  res-
ervoir for the pathogen [3]. Acute Q fever most often 
presents  with  non-specific  influenza-like  symptoms, 
and  the  infection  is  asymptomatic  in  approximately 
50% of cases. A subset of the patients develops chronic 
Q fever, a potentially life-threatening condition. Since 
2007, the Netherlands has been experiencing the larg-
est Q fever outbreak ever reported in the literature. As 
of the end of 2010 approximately 4,000 people have 
been affected and at least 14 of these patients, nearly 
all  of  them  with  severe  underlying  conditions,  have 
died.6 www.eurosurveillance.org
Methods
On the basis of a rapid risk assessment in the begin-
ning of 2010, a more comprehensive risk assessment 
was performed according to the principles of evidence-
based  medicine  (EBM)  [4].  In  March  2010,  a  work-
ing group was established at the ECDC including one 
medical librarian and five reviewers with broad epide-
miological experience. Reviews and original research 
articles  were  retrieved  from  PubMed  and  Embase 
bibliographic  databases.  The  search  strategies  cov-
ered  different  aspects  of  Q  fever:  blood,  pregnancy, 
chronic diseases, occupational exposure, transmission 
and surveillance of the disease. The concepts used in 
the search were taken from the controlled vocabulary 
available in the bibliographic databases (i.e. MeSH and 
Emtree terms). These were complemented with multi-
ple field search combinations by using natural vocabu-
lary (i.e. keywords). The results were limited to records 
published  from  1970  onwards.  The  search  was  not 
restricted to articles written in English. Studies were 
selected according to relevance for the different ques-
tions, using inclusion criteria agreed upon before the 
review process started. When in doubt about inclusion 
of a paper, it was discussed with the group of review-
ers. We included only studies reporting on outbreaks 
and  having  primary  results  from  research.  Excluding 
commentaries, editorials, single case reports.
The studies were categorised according to the follow-
ing  study  designs:  reviews,  trials  and  observational 
studies. The observational studies were sub-classified 
into  the  following  categories:  cohort  studies,  case 
series, case–control studies, case studies, cross-sec-
tional studies, time series, ‘before and after’ studies. 
The following sections were included in the evidence 
table:  bibliographic  citation,  type  of  study,  number 
of  patients  or  size  of  population,  study  outcome, 
strengths of study and limitations of study. The results 
were presented to, and discussed with, an expert panel 
with 18 representatives from the Netherlands, France, 
Germany, the United Kingdom, the United States (US), 
the European Food Safety Authority and the European 
Commission.
The  applicability  of  the  EBM  methods  was  assessed 
during the process of preparing the risk assessment in 
discussions with the panel of experts and the advisory 
forum of ECDC, and after publication of the risk assess-
ment in discussion among the team of reviewers.
Results
The risk assessment was conducted within two months 
(mid-March  to  mid-May  2010),  and  involved  six  staff 
members (at approximately half of their working time). 
A total of 559 abstracts were retrieved and read, and 
approximately 150 full text articles were selected for 
inclusion in the evidence base. A meeting with experts 
from  Europe  and  the  US  was  held  in  Paris  in  April 
2010. The full report describing the exact methodology 
including  search  strategies,  evidence  tables  and  rec-
ommendations has been published [5].
The following results regarding the four questions were 
obtained by the risk assessment:
Blood
Q fever can be transmitted through direct contact to 
blood, and cases have been reported among labora-
tory  personnel  and  pathologists  [6].  The  exact  dura-
tion  of  bacteraemia  is  unknown.  To  date  there  has 
been  only  one  documented  case  of  human-to-human 
transmission  via  blood  transfusion  [7].  One  case  of 
transmission  from  a  bone  marrow  transplant  in  an 
immunosuppressed patient has also been reported [8]. 
Q fever has also been transmitted via organ transplan-
tation in animals [9]. Donors of organs, cells or tissues 
are  not  routinely  screened  for  C.  burnetii  [10].  Blood 
donors have been examined for Q fever mainly in epi-
demic settings [11].
The following recommendations were made, based on 
the  evidence  as  described  in  the  full  report  [5],  and 
bearing the precautionary principle in mind:
•	 During  an  outbreak,  the  affected  area  should  be 
defined and safety precautions should be consid-
ered, such as screening of blood and tissue prod-
ucts, active surveillance among blood and tissue 
recipients, and screening of donors.
•	 It should be considered to defer travellers returning 
from an epidemic area from donating blood for six 
weeks after their arrival in a low-prevalence area.
•	 An antibiotic course could be considered for blood 
transfusion  recipients  at  particularly  high  risk  of 
chronic disease, such as patients with heart valve 
defects, in an epidemic area.
•	 Donors  who  have  had  an  acute  Q  fever  infection 
should be deferred from giving blood for two years 
following  the  date  of  confirmed  cure  from  acute 
infection (absence of phase 1 antibodies).
Chronic Q fever
A  cumulative  point  estimate  calculated  from  all  the 
studies included in this assessment, gave an overall 
average prevalence for chronic Q fever of 1.9% of acute 
cases. Chronic Q fever can develop after, or appear as 
an asymptomatic infection [12,13]. The fatality rate for 
chronic  Q  fever  may  vary  from  5%  to  60%  [14].  Risk 
factors for developing chronic disease are mainly con-
nected to the host and include heart valve defect, heart 
valve  prosthesis  or  arterial  graft,  aneurisms,  malig-
nancies,  and  immunosuppression.  Medical  treatment 
for  chronic  Q  fever  should  be  at  least  one  year  with 
more than one drug. The optimal treatment of chronic 
Q fever is still debated and the recommended duration 
of treatment varies from one year up to a lifespan [15]. 
Most authors today recommend broad-spectrum tetra-
cyclines,  preferably  doxycycline  in  combination  with 
hydroxychloroquine for at least 18 months [16]. During 
an outbreak, three possible strategies are described in 
the risk assessment for population-wide, targeted case 
finding and individual follow-up to identify patients at 
risk in the outbreak area: (i) Serological testing, during 7 www.eurosurveillance.org
an outbreak, of all patients with known heart valve dis-
ease or vascular grafts, in order to identify them early 
and refer them for treatment. (ii) Testing of all patients 
with  acute  Q  fever  with  echocardiography  for  heart 
valve lesions. (iii) Individual serological follow-up after 
acute Q fever infection and raising awareness among 
the  general  population  and  physicians.  An  effective 
whole-cell vaccine is used for defined risk groups in 
Australia but is not licensed or used in any other coun-
try [3].
The recommendations below are based mainly on evi-
dence from observational studies and the judgements 
from the expert panel:
•	 Acute  and  chronic  cases  need  to  be  followed  up 
individually by primary and secondary healthcare 
services.
•	 Special attention should be paid to risk groups, i.e. 
people  with  valvular  heart  disease,  vascular  dis-
eases, cancer or a compromised immune system.
•	 Among  these  risk  groups,  targeted  case-finding 
should be considered as an option.
•	 People  with  known  risk  factors  should  not  visit 
farms infested with Q fever.
•	 The formalin-inactivated whole-cell Q fever vaccine 
is effective, but pre-vaccination testing is neces-
sary  due  to  high  reactogenicity  in  persons  who 
have earlier been infected with C. burnetii, making 
the vaccine more suitable for defined risk groups 
than for general vaccination.
•	 Making the vaccine available for defined risk groups 
should be considered.
•	 There  is  need  to  initiate  good  prospective  cohort 
studies and trials with control groups when ethi-
cally feasible, to obtain more robust evidence on 
how to prevent and control outbreaks of Q fever, 
and on how to diagnose and treat acute and chronic 
disease at the clinical level.
Pregnancy
The available evidence with regard to effects of Q fever 
infection in pregnant women is limited [17]. There are 
indications  for  severe  disease  and  progress  towards 
chronic infection/disease in pregnant women. To what 
extent the risk of pregnant women for severe Q fever 
outcomes differs from the risk of the general (female) 
population and in comparison to other well-known risk 
groups cannot be quantified based on the current avail-
able evidence. The presence of C. burnetii in fetal tis-
sue after abortion or intrauterine fetal death has been 
reported, but also in healthy children delivered from 
infected mothers with placentitis. Transplacental trans-
mission seems to be possible but its association with 
adverse  obstetrical  outcomes  remains  incompletely 
understood as well as the consequences for the child 
in case of live birth. Several case reports on adverse 
pregnancy outcomes associated with maternal Q fever 
exist  [15,16,18,19].  The  largest  published  case  series 
summarising  the  serological  profiles  and  pregnancy 
outcomes of 53 women during a period of 15 years in 
southern France, found obstetric complications in 70% 
of  all  observed  pregnancies,  and  in  81%  of  the  non-
treated pregnancies [17]. So far, this case series also 
provides  some  indication  that  long-term  antibiotic 
therapy with co-trimoxazole has the potential to pre-
vent the most severe pregnancy outcomes [17].
The  evidence  led  to  the  following  conclusions  and 
recommendations:
•	 There  is  some  indication  that  long-term  antibiotic 
therapy  with  co-trimoxazole  has  the  potential  to 
prevent  severe  pregnancy  outcomes  associated 
with Q fever, but the evidence is based on a case 
series without randomisation and without control-
ling for potential biases.
•	 As  long  as  no  further  evidence  from  high  quality 
treatment  studies  is  available,  pregnant  women 
with diagnosed Q fever infection should be treated 
with  antibiotics  until  the  end  of  the  pregnancy. 
However, the scientific basis for this recommenda-
tion is weak, and ECDC would strongly recommend 
that randomised controlled trials are performed to 
obtain  more  reliable  evidence.  Pregnant  women 
should  be  advised  not  to  visit  farms  in  affected 
areas.
•	 ECDC does not recommend against breastfeeding by 
mothers with proven C. burnetii infection, except in 
cases of chronic disease that need long-term treat-
ment of the mother.
Transmission and surveillance
There is scientific evidence (experimentally, epidemio-
logically and by use of statistical models) that airborne 
transmission  of  C.  burnetii  is  the  principal  mode  of 
transmission  to  humans  [1-3].  Airborne  transmission 
includes  long-distance  (indirect)  transmission  of  the 
aerosolised bacteria and direct transmission through 
inhalation of droplets, aerosols and dust during contact 
with infected animals, contaminated animal products 
(e.g. wool or straw) and contaminated clothing [20-23]. 
An association between transmission to humans and 
environmental  factors,  i.e.  wind  speed,  dry  weather 
conditions  and  vegetation  density,  has  also  been 
established  [21,24,25].  The  distance  infectious  parti-
cles can spread by air is a point of controversy. Several 
estimates ranging from 400 m to 40 km are provided 
in  the  literature  from  different  outbreak  investiga-
tions [21,26,27]. More sound data was provided from 
a Dutch study on a Geographical Information System, 
which demonstrated that the risk of infection is high-
est within a 5 km radius from the source [28].
There have only been a few studies that describe food-
borne transmission of C. burnetii. These indicated that 
consumption of contaminated food may lead to sero-
conversion, but not to clinical disease [29]. Data from 
experiments  in  which  contaminated  milk  was  fed  to 
healthy volunteers gave no clear evidence about trans-
mission [30]. Single case reports indicate a low rate of 
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breastfeeding,  sexual  transmission,  transplacental 
transmission and spread after autopsies [31-33]. Active 
surveillance (i.e. active serological targeted case find-
ing  for  Q  fever  independent  of  clinical  symptoms) 
helped to detect cases of acute Q fever in the general 
population,  in  patients  with  valvular  heart  diseases 
or vascular grafts, and in pregnant women [34-37]. In 
epidemic  situations,  awareness  campaigns  address-
ing both the general public and medical care provid-
ers  were  successfully  used  to  enhance  case  finding 
[27,36,38].
We derived the following conclusions and recommen-
dations from the reviewed evidence:
•	 Available  evidence  suggests  an  effective  range  of 
airborne spread of C. burnetii from infested farms 
in the Netherlands of less than 5 km. The risk of 
airborne spread is therefore limited to areas close 
to outbreak sources.
•	 Active surveillance or case finding for acute Q fever 
in  risk  groups  on  a  local  level  and  for  a  defined 
period of time is reported feasible and an efficient 
method for detecting acute infections.
•	 In areas adjacent to epidemic settings (≤5 km from 
the source), awareness campaigns among health-
care providers should be initiated.
•	 If  the  area  also  affects  other  Member  States,  the 
responsible  public  health  authorities  need  to 
inform their cross-border counterparts.
•	 Sharing  of  information  between  public  health  and 
veterinary authorities would facilitate early recog-
nition of an outbreak.
Discussion
By systematically assessing the evidence for the four 
questions  from  the  European  Commission  related  to 
the Q fever epidemic in the Netherlands, we explored 
the applicability of an evidence based methodology in 
a medium-term (i.e. two to three months) public health 
risk  assessment.  When  compared  with  the  earlier 
short-term risk assessment which had been conducted 
within a few days by the ECDC, the use of EBM allowed 
us not only to refine some of the previous statements, 
but  also  to  draw  some  new  conclusions.  The  most 
remarkable  finding  was  the  lack  of  sound  evidence 
behind  some  standard  treatment  regimes  (e.g.  long-
term  co-trimoxazole  treatment  for  pregnant  women). 
This should be an incentive for the research community 
to initiate high quality studies on the effects of differ-
ent clinical and public health interventions on Q fever 
and pregnancy. This knowledge gap has also been rec-
ognised by research institutes in the Netherlands, and 
a first well designed study about screening strategies 
for Q fever among pregnant women in risk areas has 
recently been launched [39]. We were also able to pro-
vide more accurate information on the risk for chronic 
disease, and on the risk for possible spread of C. bur-
netii to neighbouring countries.
While conducting this risk assessment, we identified 
several potential problems that could make it difficult 
to conduct an EBM approach in a public health setting, 
including logistical and managerial problems, difficul-
ties in applying existing evidence rating systems, and 
difficulties in expressing uncertainties.
After  reviewing  the  process  of  developing  the  risk 
assessment,  we  found  that  endorsement  by  the  top 
management is essential to promote EBM as a core part 
of public health practice, and several steps might be 
considered by the management to foster EBM as part 
of daily working routine. It should be expected that rec-
ommendations and decisions for any scientific advice 
are  based  on  the  best  available  evidence  and  that 
appropriate methods are employed to search and ana-
lyse the evidence. We think there is a need to incorpo-
rate EBM as part of the goals and objectives for project 
managers  and  programme  leaders  in  public  health, 
and  continuous  EBM  training  should  be  established 
in organisations and institutes which are involved in 
producing  general  public  health  recommendations 
and assessments. To support the use of EBM in pub-
lic health, ECDC has established a one-week training 
course, held for the first time in November 2010, which 
has been open also to external participants since May 
2011. To work on a medium-term evidence-based risk 
assessment  within  an  organisation  where  everybody 
is preoccupied with other assignments, turned out to 
be  logistically  difficult.  The  Q  fever  risk  assessment 
was developed within a time frame of approximately 
two months, and six experts were actively involved in 
the process. A group of experienced people should be 
clearly assigned to the task and share the work to be 
able to deliver in the short time frames. We found that 
discussions with a panel of experts are mandatory, but 
the questions to be addressed and the evidence should 
be  prepared  by  the  review  team.  Experts  should  be 
selected in a transparent way, i.e. by using an exist-
ing database of experts with well defined profiles and 
conflict of interest declaration.
An evidence-based approach normally includes grad-
ing of the quality of the studies and thereafter grad-
ing of recommendations. In many settings of infectious 
disease  epidemiology,  however,  observational  stud-
ies or natural experiments are the only feasible study 
designs, i.e. evidence at the lower level of the evidence 
hierarchy  when  referring  to  the  GRADE  system  [40]. 
That was also the case in this situation. Nevertheless, 
we found that such studies can still be judged accord-
ing to their quality. A study can be of high quality even 
if its design does not fulfil the strict criteria for ’high 
quality evidence’. Existing grading systems, however, 
were perceived as not appropriate since almost all stud-
ies which were included for our risk assessment would 
have been graded very low. To enhance the information 
level  with  regard  to  study  quality  the  group  decided 
instead to indicate strengths and limitations. We found 
that there is a need to develop new tools and methods 
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from observational studies) in the field of public health 
and infectious diseases.
To  conduct  comprehensive,  evidence-based  risk 
assessments is time and resource consuming and may 
not be feasible for all the assessments required when 
threats emerge. A rapid assessment, conducted within 
few days of the occurrence of an event, is often needed 
to provide immediate guidance. It relies on review of 
easily  assessable  evidence  from  different  sources, 
including  review  articles,  websites  of  internationally 
recognised organisations and textbooks, which might 
be outdated, not transparent on conclusions and pre-
senting diverging views. It is hardly possible, however, 
to apply the classical evidence-based methodology on 
a two-day risk assessment, and EBM was not designed 
to do so. On the other hand, these constraints are no 
justification  for  disregarding  the  principles  of  EBM 
when  conducting  rapid  risk  assessments:  transpar-
ency, reproducibility and validity of all scientific advice 
given to the public, to professionals or to other stake-
holders. Following these principles under pressure of 
time will probably reveal a higher level of uncertainty 
about  the  conclusions  and  recommendations  when 
compared to medium- or long-term risk assessments. 
We are aware that it is difficult, especially for public 
health agencies, to translate scientific uncertainty into 
policy advice. Stakeholders expect certainty and clear 
answers. However, we also believe that public health 
advice and policy is most consistent if scientific uncer-
tainty is included in the assessment and the decision-
making  process  as  information,  not  ignorance.    The 
decision of starting a full assessment should balance 
the  expected  benefits  against  the  resources  needed 
and the time it will take to produce it. There is need 
to  define  indications  for  doing  evidence-based  risk 
assessments under different time constraints.
In  this  assessment  we  tested  whether  an  evidence-
based approach, comparable to the methodology used 
in  clinical  medicine  is  appropriate  for  giving  public 
health  advice  under  an  ongoing  outbreak.  We  found 
that an evidence-based approach is feasible for pro-
viding  an  intermediate-term  risk  assessment  within 
two to three months. Working explicitly and transpar-
ently with methods, evidence and experts will result in 
higher quality of public health advice.
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Large  outbreaks  of  Q  fever  in  the  Netherlands  from 
2007 to 2009 were monitored using notification data 
of acute clinical Q fever. However, the notification sys-
tem provides no information on infections that remain 
subclinical or for which no medical attention is sought. 
The present study was carried out immediately after 
the peak of the 2009 outbreak to estimate the ratio 
between Coxiella burnetii infections and Q fever noti-
fications. In 23 postcode areas in the high-incidence 
area, notification rates were compared with serocon-
version rates in blood donors from whom serial sam-
ples were available. This resulted in a ratio of one Q 
fever notification to 12.6 incident infections of C. bur-
netii. This ratio is time and place specific and is based 
on a small number of seroconversions, but is the best 
available  factor  for  estimating  the  total  number  of 
infections. In addition, as subclinical C. burnetii infec-
tion may lead to chronic Q fever, the ratio can be used 
to  estimate  the  expected  number  of  chronic  Q  fever 
patients  in  the  coming  years  and  as  input  for  cost–
benefit analyses of screening options.
Introduction
Q fever is a zoonosis caused by Coxiella burnetii. The 
bacterium  has  a  worldwide  distribution  in  domesti-
cated  and  wild  animals,  but  transmission  to  humans 
is  mostly  associated  with  sheep  and  goats  [1].  Most 
patients with Q fever recover after mild febrile illness; 
others may experience pneumonia, hepatitis or, more 
rarely, myocarditis or central nervous system complica-
tions [2]. Because the clinical presentation of acute Q 
fever is rather non-specific, laboratory confirmation is 
essential. C. burnetii has two antigenic phases (I and 
II) and with serological assays, IgM II, IgG II, IgM I and 
IgG I antibodies are used to distinguish between acute 
infection and chronic infection.
From 2007 to 2009, the Netherlands faced large sea-
sonal  outbreaks  of  Q  fever,  with  the  highest  peak 
in  2009  [3].  Surveillance  of  Q  fever  is  mandatory  in 
European Union (EU) countries. In 2009, a total of 370 
Q fever cases were reported in 24 EU countries, apart 
from  the  2,317  cases  from  the  2009  outbreak  in  the 
Netherlands [4]. The low number of notifications is in 
contrast to results from seroprevalence studies, which 
suggest  that  2–10%  of  the  general  population  in  EU 
countries  have  previously  been  infected  with  C.  bur-
netii [1]. People with a C. burnetii infection will only be 
notified as Q fever cases to the national public health 
authorities  if:  (i)  they  have  symptoms;  (ii)  they  seek 
medical attention; (iii) have been tested with a Q fever 
diagnostic laboratory test; (iv) the test is sensitive and 
shows a positive result; (v) the physician or laboratory 
notifies the case to the local public health authorities; 
and (vi) the local public health authorities confirm that 
the  notification  criteria  are  fulfilled  and  reports  the 
case to the national public health authorities. Each of 
these steps has an influence on the difference between 
the true number of infections and the number of noti-
fications.  However,  little  is  known  about  the  relative 
importance of the various steps.
An estimate much cited in the international literature 
is that 40% of C. burnetii infections are symptomatic 
[2,5]. However, this estimate is based on just one origi-
nal study, from an outbreak in Switzerland in 1983, in 
which 191 (46%) of 415 serologically confirmed cases 
were symptomatic [6]. Hardly any information is avail-
able on the health-seeking behaviour of symptomatic 
patients.  Symptomatic  C.  burnetii  infection  (Q  fever) 
may  resemble  influenza-like  illness,  for  which  only 
an  estimated  20%  in  the  Netherlands  seek  medical 
care [7] and for which most general practitioners will 
not  request  a  laboratory  test.  Low  sensitivity  of  the 12 www.eurosurveillance.org
laboratory test and failure to report a diagnosis of Q 
fever are probably of minor importance during a period 
in which there is a high number of incident cases and 
both the physician and laboratory are legally required 
to notify cases.
Before the recent Q fever epidemic in the Netherlands, 
the seroprevalence of 2.4% in the general population 
was  relatively  low  in  comparison  with  that  in  other 
countries  [8].  The  epidemic  resulted  in  an  unprece-
dented number of 3,522 laboratory-confirmed Q fever 
cases notified from 2007 to 2009 [9]. Policy decisions 
on  veterinary  interventions  were  to  a  large  extent 
based on close monitoring of these human Q fever noti-
fications. With the declining number of Q fever notifica-
tions in 2010, attention has shifted to the increasing 
number of patients with long-term effects of acute Q 
fever, especially Q fever fatigue syndrome and chronic 
Q  fever.  The  number  of  asymptomatic  infections  is 
relevant in this context, because asymptomatic infec-
tions can also lead to chronic Q fever, mostly in people 
with risk factors such as cardiac valve disease, aneu-
rysm,  vascular  graft  or  pregnancy  [10].  Knowing  the 
total number of persons infected, including those with 
asymptomatic infections, would allow better estimates 
of the expected number of chronic disease cases. There 
are  also  other  remaining  public  health  policy  ques-
tions that pertain to screening of blood, semen, tissue 
and organ donors, pregnant women and patients with 
cardiac  valve  or  vascular  disease  for  asymptomatic 
infection.  For  these  reasons,  having  an  estimate  of 
the number of infections is important for public health 
policy.  The  present  study  therefore  focuses  on  the 
ratio of the incidence of C. burnetii infection to that of 
notified Q fever cases during the 2009 outbreak in the 
Netherlands  by  relating  the  number  of  blood  donors 
with seroconversion to figures from the national infec-
tious diseases notification system.
Methods
Notifications
We  used  data  on  notifications  for  1  June  2009  to  31 
January 2010 from the 23 postcode areas in the south 
of the Netherlands that had the highest incidence of 
notified  Q  fever  cases  between  weeks  26  and  37  of 
2009 (22 June to 13 September) [11]. According to Dutch 
legislation, the attending physician and the head of the 
medical microbiology laboratory must notify any diag-
nosis of acute Q fever to the municipal health service. 
Of the 23 postcode areas, 21 were under the municipal 
health service ‘Hart voor Brabant’ and two were under 
a neighbouring municipal health service. The munici-
pal  health  services  interviewed  the  notified  patients 
and  entered  information  on  those  who  fulfilled  the 
notification  criteria  into  the  national  infectious  dis-
eases  surveillance  database.  Notification  criteria  of 
acute Q fever were a clinical presentation with fever or 
pneumonia or hepatitis, in combination with a positive 
laboratory result indicating acute C. burnetii infection. 
The laboratory criteria were a fourfold IgG titre rise or 
more  measured  by  immunofluorescence  assay  (IFA), 
enzyme-linked immunosorbent assay (ELISA) or com-
plement fixation test, a positive IgM phase II antibody 
test or detection by polymerase chain reaction (PCR) of 
C. burnetii DNA in blood or respiratory material.
Blood donors
Sanquin Blood Supply Foundation is the only organisa-
tion in the Netherlands authorised to manage the sup-
ply of blood and blood products. To assess the safety 
of  donated  blood,  samples  of  blood  donations  from 
people living in the most affected area were collected 
by Sanquin over a one-year period from 20 May 2009. 
From  this  collection,  donations  from  people  living  in 
the 23 postcode areas with the highest incidence were 
tested for the presence of antibodies against C. bur-
netii.  Details  of  the  study  have  been  reported  else-
where [11]. Briefly, serological data were generated of 
the 543 donors who donated more than once in the first 
eight months of the study (20 May 2009 to 15 January 
2010). The donor’s last donation was screened for the 
presence  of  IgG  antibodies  to  phase  II  of C.  burnetii 
using a commercial ELISA (Serion, Clindia Benelux, the 
Netherlands).  All  ELISAs  that  gave  borderline  results 
(IgG  levels  of  20–30  international  units  (IU)/ml)  or 
positive (>30 IU/ml) sera were confirmed by IFA (Focus 
Diagnostics,  United  States).  An  IgG  II  antibody  titre 
of ≥1:64 was considered positive in the IFA. If the last 
donation  tested  positive,  the  donor’s  previous  dona-
tion was also tested in the same way.
The mean age of the 543 donors was 49.5 years (range: 
19–70  years)  and  60.4%  were  male  (n=328).  Due  to 
Sanquin  privacy  regulations,  information  on  age  and 
sex at the individual donor level was not available.
Data analysis
The incidence of infection was calculated by dividing 
the  number  of  blood  donors  with  seroconversion  by 
the person-time of follow-up. As population figures by 
postcode area were available by five-year age groups 
[12],  we  used  the  age  range  20–69  years  instead  of 
19–70 years.
The incidence of notified acute Q fever cases was cal-
culated by dividing the number of notifications of per-
sons aged 20–69 years with a date of symptom onset 
between 1 June 2009 and 31 January 2010 by the total 
number of people aged 20–69 years living in the 23 
postcode areas on 1 January 2010 (n=55,715).
Results
Notifications
The number of acute Q fever notifications (all ages) in 
the 23 postcode areas was 75 in 2007, 323 in 2008 and 
570  in  2009  (Figure).  There  were  167  notifications  of 
cases aged 20–69 years who had a date of symptom 
onset between 1 June 2009 and 31 January 2010.
 The mean age of the 167 notified cases was 45.6 years 
and 53.9% (n=90) were male. With a population size of 
55,715, the incidence of notified cases was 4.5 (95% 13 www.eurosurveillance.org
confidence  interval  (CI):  3.9–5.2)  per  1,000  persons 
per year.
Infections
Of the 543 people who donated blood more than once 
during 20 May 2009 to 15 January 2010, 66 tested posi-
tive or borderline for C. burnetii IgG antibodies in the 
last  donation  [11].  All  66  ELISA-reactive  sera  had  a 
phase  II  IgG  antibody  titre  ≥1:64  in  the  confirmatory 
IFA. The phase II IgG seroprevalence in the 23 postcode 
areas  was  therefore  12.2%  (95%  CI:  9.7–15.2).  When 
the  previous  donation  of  the  66  seropositive  donors 
was tested, 10 of the 66 sample pairs were identified 
as seroconversions for IgG phase II. In two of the 10 
donors, the seroconversion was from a weak antibody 
response to at least a fourfold higher titre in the IFA in 
the last donation; for the other eight donors, no anti-
bodies were detected at all in the previous donations.
The cumulative follow-up period for the 487 (543 minus 
56)  donors  without  C.  burnetii  IgG  antibodies  in  the 
previous donation was 64,135 days. With 10 serocon-
versions observed, the C. burnetii infection incidence 
was 56.9 (95% CI: 31.2–101.4) per 1,000 person-years. 
This point estimate translates into 2,113 (95% CI: 1,159–
3,766) new infections among those aged 19–70 years in 
the study area over the eight-month study period.
On the basis of the notifications and seroconversions, 
there was a ratio of one Q fever notification to 12.6 inci-
dent infections of C. burnetii – i.e. 7.9% of the infec-
tions that occurred in the area were notified.
Discussion
The study provides an estimate of incidence of infec-
tion with C. burnetii in relation to incidence of notified 
acute Q fever cases. It suggests that the 3,522 acute Q 
fever cases that were notified in the Netherlands from 
2007 to 2009 correspond to more than 44,000 infec-
tions in the same period. This rough estimate is likely 
to  be  an  underestimation  as  underreporting  outside 
the  high-incidence  study  area  was  probably  higher. 
However, our study pertains to a particular time and 
area: the estimate for the entire epidemic is indicative 
only and should be interpreted with caution.
In the village where the first outbreak in 2007 occurred, 
443 inhabitants provided a blood sample, of which 73 
(16.5%) showed a recent infection [13]. Of these 73 peo-
ple,  48  had  symptoms  that  could  be  attributed  to  Q 
fever. This suggests that 66% were symptomatic infec-
tions. However, the actual percentage of symptomatic 
infections is likely to be lower, as symptoms are non-
specific and could easily have been misclassified as Q 
fever-related.
Figure 
Notifications for acute Q fever in 23 postcode areas in the high-incidence area of the Netherlands, 2007–2010
The arrowed line indicates the study period for collection of notification data (1 June 2009 to 31 January 2010).
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Even if we accept the prevailing estimate from the inter-
national  literature  that  40%  of  C.  burnetii  infections 
are symptomatic, it is clear that a large proportion of 
symptomatic  cases  do  not  seek  medical  attention  or 
are  not  diagnosed  as  acute  Q  fever  patients.  It  is  a 
common  finding  that  surveillance  systems  have  low 
reporting efficiency for infectious diseases with mild 
or non-specific symptoms [14].
The  proportion  of  infections  that  is  not  notified 
because patients do not seek medical attention or a 
diagnostic test is not requested, is neither fixed nor 
random, but is highly affected by certain factors, such 
as media attention or physicians’ awareness that a par-
ticular pathogen is circulating. At the time of study in 
the second half of 2009, awareness of Q fever among 
patients and general practitioners in this area was at 
a high level [15]. In combination with easy availability 
of diagnostic facilities in the area, we can expect that 
a  larger  proportion  of  symptomatic  C.  burnetii  infec-
tions were diagnosed as acute Q fever compared with 
areas with lower awareness and where laboratory tests 
for C. burnetii infection were not routinely available to 
general practitioners. Raoult et al. showed a high inci-
dence of Q fever around the French National Reference 
Centre  for  Rickettsial  Diseases  (in  Marseille,  France) 
[16], suggesting high levels of awareness and testing 
in this area. Conversely, in a low-incidence situation, 
the  absolute  number  of  cases  that  are  not  notified 
would be low, while the proportion of infections that 
is not notified could be high. This will especially be the 
case when the beginning of an outbreak passes largely 
unnoticed. This happened in 2007 in the Netherlands, 
when  increasing  numbers  of  pneumonia  cases  were 
first  thought  to  be  due  to  Mycoplasma  pneumoniae 
infection. Retrospectively, a number of clusters of hos-
pital  admissions  for  respiratory  tract  infections  were 
identified that occurred in 2005 to 2007 – earlier than 
the  recorded  Q  fever  outbreaks  –  which  could  have 
been  Q  fever  because  there  was  a  Q  fever-affected 
farm nearby and there was no alternative explanation 
for the cluster [17].
A  limitation  of  our  study  is  that  in  general,  healthy 
adult blood donors poorly represent the general popu-
lation. However, Q fever is an airborne infection, thus 
reducing biases caused by the comparison of donors 
with the general population [11]. The age and sex distri-
bution of the donors in the study population was very 
similar  to  those  of  the  notified  Q  fever  cases  in  the 
Netherlands (mean age of 50 years, 62% male) over the 
entire epidemic period from 2007 to 2009 [3]. We had 
no information on addresses of blood donors and could 
therefore not correct for possible differences between 
donors and notified Q fever patients in the proximity of 
their places of residence to infected farms.
The  12.2%  seroprevalence  among  blood  donors  sug-
gests  that  approximately  6,800  people  in  the  age 
group 20–69 years in the study area had been infected 
at the time of the study, i.e. after the 2007 and 2008 
outbreaks  and  half-way  through  the  2009  outbreak. 
This estimated number of prevalent cases seems low 
in comparison with the number of notifications and the 
estimated incident infections. It illustrates that in relat-
ing incidence to prevalence, other parameters have to 
be taken into account such as the decay rates of anti-
body titres.
In conclusion, our study suggests that during the peak 
of the epidemic in the Netherlands, every notification 
of clinical Q fever represented more than 12 infections 
with  C.  burnetii.  Despite  uncertainties  surrounding 
the  clinical  significance  of  asymptomatic  seroconver-
sion, this ratio could be used as one factor to estimate 
the number of chronic Q fever patients that could be 
expected in the coming years and as input for cost–
benefit analyses of screening options.
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From 2007 to 2009, the Netherlands faced large sea-
sonal  outbreaks  of  Q  fever,  in  which  infected  dairy 
goat  farms  were  identified  as  the  primary  sources. 
Veterinary  measures  including  vaccination  of  goats 
and sheep and culling of pregnant animals on infected 
farms seem to have brought the Q fever problem under 
control. However, the epidemic is expected to result in 
more cases of chronic Q fever among risk groups in the 
coming years. In the most affected area, in the south 
of the country, more than 12% of the population now 
have  antibodies  against  Coxiella  burnetii.  Questions 
remain about the follow-up of acute Q fever patients, 
screening of groups at risk for chronic Q fever, screen-
ing of donors of blood and tissue, and human vaccina-
tion. There is a considerable ongoing research effort as 
well as enhanced veterinary and human surveillance.
Introduction
Acute Q fever was made mandatorily notifiable in the 
Netherlands  in  1975,  but  was  rarely  reported  from 
1975 to 2006 (with between one and 32 notifications 
per year). In 2005, Q fever was diagnosed on two dairy 
goat farms with unusually high numbers of abortions 
and two years later, in 2007, it emerged in the human 
population  in  the  south  of  the  Netherlands.  This 
was the start of an exceptionally large epidemic that 
showed a marked seasonality and expanded both geo-
graphically and in size in 2008 and 2009. From 2007 
to 2009, more than 3,500 human cases were notified. 
The observation that human cases mainly occurred in 
the same area as dairy goat farms with Q fever-induced 
abortion waves provided circumstantial evidence that 
dairy  goat  farms  were  the  most  plausible  source  of 
human  infection  in  this  epidemic.  The  patients  most 
affected  were  men,  smokers  and  aged  40–60  years, 
while children were rarely affected [1]. Acute Q fever 
mainly presents as febrile illness, pneumonia or hepa-
titis, but clinical presentation may vary from one area 
to another [2]. More than 92% of notified patients in 
the  Netherlands  with  onset  of  illness  in  2007  and 
2008 had fever, while 62% presented with pneumonia 
[1]. Hepatitis was reported in less than 1% of notified 
patients but is a common presentation of acute Q fever 
in some countries such as France [2]. The diagnosis Q 
fever can only be made after confirmation with a labo-
ratory test. Serological methods can detect antibodies 
against phase I and phase II antigens of Coxiella bur-
netii, the causative agent of Q fever, and thereby dis-
tinguish  acute  from  chronic  disease.  Annual  updates 
on the Q fever epidemic in the Netherlands have been 
published in this journal [3-5]. We now report on the 
current  situation  in  the  aftermath  of  the  epidemic, 
focusing on the challenges and remaining questions, 
especially with respect to chronic Q fever.
Decreasing incidence of acute Q fever,  
increasing seroprevalence
The epidemiological situation in the aftermath of the 
epidemic  can  be  characterised  by  a  decreased  inci-
dence of notifications of acute Q fever and an increased 
prevalence of antibodies to C. burnetii in the general 
population, particularly in the most affected area in the 
south of the country. The number of notified acute Q 
fever patients fell from 2,354 in 2009 to 504 in 2010 
(Figure). From January to November 2011, 81 patients 
were notified, which is far fewer than the same period 
in the epidemic years, despite the exceptionally warm 
and  dry  weather  conditions  in  the  spring  of  2011, 
which are considered conducive to airborne spread of 
C. burnetii.17 www.eurosurveillance.org
It  is  difficult  to  attribute  the  decrease  in  incidence 
in  2010  and  2011  to  any  particular  control  measure 
because  several  veterinary  interventions  were  imple-
mented  at  the  same  time.  In  April  2009,  vaccination 
of sheep and goats on dairy farms with more than 50 
animals and on farms with public functions in the high-
incidence area became mandatory and was extended 
to  the  entire  country  in  January  2010  [6].  In  addi-
tion,  stringent  hygiene  measures  were  implemented, 
such  as  safe  manure  management  and  hygiene  dur-
ing lambing. In October 2009, mandatory monitoring 
of bulk tank milk was implemented. In addition, from 
December 2009 to June 2010, more than 50,000 preg-
nant goats and sheep were culled on 87 farms in which 
bulk tank milk was positive for C. burnetii.
Increasing  immunity  and  thereby  a  smaller  popula-
tion at risk among the general population in the high-
incidence  area  might  also  have  played  a  role  in  the 
decrease in incidence of acute Q fever. Seroprevalence 
among the general population of the Netherlands was 
only 2.4% during February 2006 to May 2007, before 
the first outbreak in June 2007 [7]. More recent nation-
wide figures are not available, but in the high-incidence 
area, seroprevalence estimates are available for preg-
nant women in 2007 to 2009 (9.0%) [8] and for blood 
donors in 2009 (12.2%) [9].
Chronic Q fever
Despite the decreasing incidence of acute Q fever, the 
Q fever problem is not over: a rising number of chronic 
Q fever patients are seen. An estimated 2% of acute Q 
fever patients develop chronic Q fever months to years 
after  the  acute  infection  [10].  Chronic  Q  fever  mainly 
presents as endocarditis or vascular infection and car-
ries a high morbidity and mortality. Infected patients 
with  previous  cardiac  valve  pathology,  aneurysms  or 
vascular  grafts  or  who  are  immunocompromised  and 
women  who  are  infected  during  pregnancy  are  most 
at risk of developing chronic Q fever [2]. Diagnosis of 
chronic Q fever is based on a combination of the follow-
ing: PCR analysis positive for C. burnetii in blood or tis-
sue in the absence of an acute infection, an IgG phase I 
antibody titre of ≥1:1,024, presence of clinical risk fac-
tors, presence of clinical signs, and radiological imag-
ing  results  including  echocardiography  and  positron 
emission tomography-computed tomography (PET-CT) 
[11]. There is no notification system for chronic Q fever 
in the Netherlands, but based on personal communica-
tions from various Dutch hospitals in September 2011, 
we estimate that a total of over 250 patients have been 
diagnosed since the start of the epidemic.
The  major  challenge  in  the  Netherlands  is  therefore 
early detection and treatment of patients who are at 
risk for chronic Q fever. The following issues are of par-
ticular relevance: (i) the follow-up strategy of acute Q 
fever patients, for the early detection and prompt treat-
ment of chronic Q fever; (ii) the screening of people in 
risk groups for chronic Q fever; (iii) the protection of 
people in risk groups through vaccination; and (iv) the 
possibility  of  person-to-person  transmission  through 
infected blood or tissue.
Figure 
Acute Q fever notifications, the Netherlands, 1 January (week 1) 2007–30 November (week 48) 2011
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It is expected that the number of patients with chronic 
infection will increase in the Netherlands the coming 
years. In order to diagnose and treat chronic Q fever 
patients in a consistent way, new guidelines are cur-
rently being developed for the diagnosis of chronic Q 
fever in the country.
Follow-up of acute Q fever patients
In the early stages of the epidemic, the internationally 
recommended  follow-up  strategy  was  followed,  con-
sisting of at least three consecutive serological tests 
in the first year after the diagnosis of acute Q fever and 
echocardiography for all patients diagnosed with acute 
Q  fever  [12].  However,  of  134  Dutch  Q  fever  patients 
from the 2007 and 2008 outbreaks who had undergone 
screening echocardiography and were followed up for 
one year after diagnosis of acute infection, none pro-
gressed to a chronic infection and echocardiographic 
screening was discontinued [13]. However, the policy of 
discontinuing  echocardiographic  screening  has  been 
challenged by Raoult et al., on the basis of data from 
France  that  show  that  clinically  silent  valvulopathies 
predispose to chronicity [14]. Considerable uncertain-
ties also exist about the value of serology to identify 
chronic cases during follow-up. At the regional labora-
tory of the Jeroen Bosch Hospital (in ´s-Hertogenbosch), 
located  at  the  epicentre  of  the  Dutch  outbreaks,  the 
serological  profiles  of  686  patients  diagnosed  with 
acute Q fever in 2007 and 2008 were evaluated at three, 
six and 12 months after diagnosis [15]. The results dif-
fer from data provided by others, as high IgG phase I 
antibody titres at the three-month follow-up were not 
predictive for chronic Q fever and IgG phase I antibody 
titres  greater  than  IgG  phase  II  antibody  titres  were 
rarely seen. The study confirmed that a cut-off value of 
≥1:1,024 for IgG phase I titres is suitable for screening in 
the commercially available immunofluorescence assay 
used (Focus Diagnostics, United States), at a follow-up 
between six and 12 months after the acute Q fever epi-
sode. For patients with clinical risk factors, however, 
a more stringent follow-up scheme is required. Wide 
variation in serological and PCR test results during the 
follow-up of acute Q fever [15] implies that the diagno-
sis of chronic Q fever – necessitating long-term anti-
biotic treatment – must be based on a combination of 
laboratory  results,  radiological  imaging  and  clinical 
grounds. On the basis of the experience gained since 
2007, the follow-up strategy is now generally one sero-
logical analysis nine months after an episode of acute 
Q fever. For patients with specific risk factors, the pre-
vious serological follow-up strategy at three, six and 
12 months is maintained, with use of PCR if high IgG I 
titres are obtained.
Screening of risk groups for chronic Q fever
Chronic Q fever has been diagnosed in the Netherlands 
in patients who had no history of acute Q fever, sug-
gesting that chronic Q fever can develop after asympto-
matic infection or symptomatic infection with only mild 
aspecific symptoms. The incubation period of a chronic 
infection is largely unknown and may be different in 
patients  with  vascular  disease  compared  with  those 
who  have  valvular  disease.  Some  hospitals  in  the 
high-incidence  area  are  now  implementing  screening 
programmes  for  the  detection  of  chronic  Q  fever  in 
patients with known cardiac valve or vascular pathol-
ogy. The risk of chronic Q fever in other risk groups, 
such as pregnant women, is probably too low to war-
rant a targeted screening strategy.
Human vaccination
Q fever can be prevented by a vaccine that is produced 
and  licensed  in  Australia  to  protect  abattoir  workers 
[16]. For this and other occupational risk groups, such 
as sheep shearers and farmers of ruminants, the vac-
cine has proved to be successful and is still in use in 
Australia [17]. From the notification data, it is clear that 
occupational exposure did not play an important role 
in the epidemic in the Netherlands [1]. The prevalence 
of  antibodies  against  C.  burnetii  in  dairy  goat  farm-
ers and practising veterinarians is greater than 80%, 
but very few seem to develop clinical disease (unpub-
lished data). Vaccination – a one-off campaign during 
the epidemic – was therefore primarily considered for 
persons at risk for chronic Q fever. Implementing vac-
cination was difficult, however, because the vaccine is 
not registered in any European country and its effec-
tiveness has only been shown in healthy young adults, 
not  in  persons  with  cardiovascular  risk  factors  or 
patients with severe underlying disease [18]. Moreover, 
the logistics are cumbersome: the vaccine can only be 
given to those who have not previously been in con-
tact with C. burnetii, as vaccinating people who have 
already  mounted  an  immune  response  against  the 
pathogen may lead to serious adverse reactions such 
as sterile abscesses and systemic symptoms of inflam-
mation. Therefore, serology and skin testing are man-
datory before vaccination. In the absence of a licence, 
the vaccine can only be administered after the patients’ 
physician has signed a medical awareness statement 
and the patient has signed an informed consent form. 
Nevertheless,  the  Health  Council  of  the  Netherlands 
advised vaccination of people in specific risk groups 
in the high-incidence area who have an increased risk 
of developing complications following acute infection 
[19]. The groups included patients:
•	 who have had endocarditis
•	 with prosthetic heart valves
•	 with important congenital heart anomalies, includ-
ing those that required grafts
•	 with structural defects of the aortic or mitral valve
•	 with known aneurysm of the aorta
•	 with vascular grafts
•	 with  severe  peripheral  vascular  disease  (such  as 
Buerger’s disease).
General practitioners selected all patients from these 
groups  from  their  patient  registration  systems.  In 
total, 1,781 patients were screened: 394 (22%) could 
not  be  vaccinated  because  of  a  positive  skin  test  or 
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screening,  21  eligible  patients  declined  vaccination 
or did not attend the vaccination session: eventually 
1,366 patients were vaccinated from 28 January to 27 
June 2011. There is a routine follow-up of vaccinated 
individuals  for  vaccine-related  adverse  events  –  the 
results should be available by the end of 2011. The vac-
cination campaign has also been followed by a post-
vaccination immune-response study in which humoral 
and cell-mediated immunity will be investigated.
Transmission of C. burnetii by infected 
blood and tissue
Although only few cases have been clearly documented, 
there is a theoretical possibility that C. burnetii can be 
transmitted  through  blood  transfusion,  and  semen, 
tissue  and  organ  donation  [20].  Active  screening 
was  therefore  recommended  by  the  European  Centre 
for  Disease  Prevention  and  Control  (ECDC)  in  their 
risk  assessment  in  2010  [10].  Sanquin  Blood  Supply 
Foundation tested blood donated from people living in 
the area with highest Q fever incidence in the south of 
the Netherlands for the presence of C. burnetii DNA by 
PCR from 20 May 2009 – in 2009 as part of a research 
project,  then  in  2010  as  a  screening  instrument  [9]. 
In  1,004  blood  donations,  there  were  three  positive 
PCR results and in one recipient, there was evidence 
of seroconversion. However, the recipient lived in the 
high-incidence  area  and  it  is  therefore  possible  that 
the infection was caused by environmental exposure. 
The  screening  programme  was  discontinued  on  1 
November 2010, when it was clear that the incidence of 
the disease had fallen dramatically. With the decreas-
ing incidence and the expected increasing numbers of 
chronic infections in the coming years, the issue of pro-
tecting recipients of blood, semen, tissue and organs 
is  shifting  towards  detecting  asymptomatic  persons 
harbouring C. burnetii months to years after their acute 
infection.  However,  there  are  important  logistic  and 
financial  constraints  in  using  PCR  on  a  large  scale. 
Capacity for PCR testing at Sanquin is limited to 100 
samples per day, while close to a million blood com-
ponent transfusions are given annually. Alternatively, 
donors  could  be  screened  for  the  presence  of  IgG 
phase I antibodies against C. burnetii. For large-scale 
screening purposes, an automated ELISA would have to 
be used, but the performance of ELISAs for IgG phase I 
antibodies have yet to be evaluated.
In August 2011, the Health Council of the Netherlands 
advised that a detailed cost-effectiveness analysis of 
serological testing of blood donors be carried out and, 
should the incidence of acute Q fever increase again, 
screening of blood donors be resumed [20]. Concerning 
tissue  donations,  no  screening  is  needed  for  tissues 
that carry a low risk of transmission such as cornea, 
coagulants and other treated blood products or tissues 
collected before 2007. Otherwise, nationwide serologi-
cal testing is recommended. In certain circumstances, 
such  as  organ  transplantation  or  use  of  stem  cells, 
the  responsible  physician  and  patient  might  decide 
to use infected material anyway, when a considerable 
improvement in quality of life or even the saving of life 
is  anticipated.  Knowing  that  the  donor’s  serological 
status is positive can then make appropriate antibiotic 
prophylactic treatment of the recipient possible.
Persistent fatigue after acute Q fever
While relatively few patients who have had acute infec-
tion develop chronic Q fever, a much larger group suf-
fers from persistent fatigue and other long-term effects 
of acute infection. Unlike chronic Q fever, this is not a 
life-threatening condition, but the fatigue can be debil-
itating and seriously affect the person’s quality of life 
[21]. In an ongoing study, the effectiveness of antibi-
otic treatment is being compared with cognitive behav-
ioural therapy for post acute Q fever fatigue.
Outlook
We  expect  that  the  sustained  mandatory  vaccination 
of goats and sheep will control transmission of Q fever 
to  humans.  The  veterinary  vaccine  seems  effective 
in reducing shedding of C. burnetii and in preventing 
abortion [22]. However, the bacteria are widespread in 
the environment and in other animal reservoirs, such as 
wild rats [23]. Enhanced surveillance in animal popula-
tions as well as in humans will remain essential. To fill 
the remaining knowledge gaps, there is an extensive 
ongoing research agenda, covering fields such as as 
host–pathogen characteristics, transmission and risk 
factors, chronic Q fever and treatment of post acute Q 
fever fatigue.
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In  Europe  the  incidence  of  human  Q  fever  has  dra-
matically increased over the previous years. Untreated 
infections  with  Coxiella  burnetii,  the  causal  agent 
of Q fever, have been associated with both obstetric 
and maternal complications. The majority of pregnant 
women  with  a  C.  burnetii  infection  remain  asympto-
matic,  hence  screening  could  be  of  value  to  prevent 
unwanted outcomes in this high-risk group. We applied 
the updated Wilson and Jungner criteria to review the 
evidence for routine screening for C. burnetii infection 
during  pregnancy.  Since  much  uncertainty  remains 
about  the  incidence,  clinical  consequences,  diag-
nostics and treatment of C. burnetii infection during 
pregnancy,  routine  screening  for  C.  burnetii  infec-
tion  during  pregnancy  should  not  be  recommended. 
Rigorous studies to assess the effectiveness of C. bur-
netii screening are warranted.
Introduction
Infections  during  pregnancy  may  cause  a  threat  to 
both maternal and foetal health, even if the infected 
pregnant  woman  herself  remains  asymptomatic  [1]. 
Therefore, routine screening at 12 weeks of gestation is 
being offered to all Dutch pregnant women for human 
immunodeficiency virus (HIV), Treponema pallidum and 
hepatitis B virus (HBV). The incidence of human Q fever, 
a zoonosis caused by Coxiella burnetii, showed an enor-
mous increase in the Netherlands and other European 
countries over the past few years [2]. Since there is evi-
dence for infection-associated obstetric and maternal 
complications, C. burnetii infection poses a potential 
risk  to  pregnant  women  and  their  (unborn)  children 
[3].  Most  of  the  pregnant  women  with  a  C.  burnetii 
infection  remain  asymptomatic  [4].  Therefore  routine 
screening has been put forward for early detection and 
treatment in this group, but scientific evidence about 
the usefulness of such an intensive program is lack-
ing. In this review we applied the Wilson and Jungner 
criteria according to the World Health Organization to 
scrutinise the available evidence for routine screening 
for C. burnetii infection during pregnancy. These crite-
ria were developed over 40 years ago but are still of 
great value in decision making around screening poli-
cies [5]. The criteria centre on the problem caused by 
the infection or disease, the screening population, the 
test and the treatment, and the costs. As newer policy 
tools,  especially  concerning  genetic  screening,  have 
been suggested [6], we also integrated the emerging 
criteria  which  are  applicable  to  our  research  ques-
tion. A review of the literature was done by searching 
PubMed  and  the  references  of  included  papers.  Our 
search was limited to studies in English or Dutch. The 
search  strategy  included  the  keywords  ’Q  fever’  or 
‘Coxiella burnetii’ and keywords related to the criteria 
(‘incidence’ or ‘prevalence’ or ‘pregnancy’ or ‘risk fac-
tors’ or ‘diagnosis’ or ‘treatment’ or ‘costs’). Our over-
all aim was to examine the evidence base for routine 
C. burnetii screening among pregnant women in high-
risk areas for Q fever all over Europe.
The problem
Terminology used in the scientific literature concerning 
’Q fever‘ is diverse and therefore direct comparisons of 
epidemiological studies should be performed with cau-
tion. ‘Q fever’ is commonly referred to the symptomatic 
disease, including symptoms such as fever, hepatitis 
or  pneumonia  in  combination  with  positive  antibody 
titres  or  polymerase  chain  reaction  (PCR).  The  terms 
‘C. burnetii infection’ and ‘presence of antibodies’ are 
more often used in the context of asymptomatic dis-
ease, for example, in prevalence studies.
Is Coxiella burnetii infection during 
pregnancy an important health problem?
Prior  to  2007  Q  fever  was  uncommon  in  Europe  [2], 
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in Germany in spring 2005, causing 331 cases [7]. In 
the Netherlands around 10 to 30 cases have been noti-
fied each year since 1977. Between 2007 and 2009 the 
numbers briskly increased to over 2,300 cases in 2009, 
the highest number ever reported in the literature [8]. 
Veterinary outbreaks on several dairy goat and sheep 
farms in the southern parts of the Netherlands are held 
responsible for this increase. In 2009 and 2010 it was 
decided to implement extensive measures such as vac-
cinating and culling of thousands of animals [8]. As a 
result, the number of human Q fever cases decreased 
rapidly to around 500 cases by the end of 2010, which 
is still considerable and may indicate an endemic stage 
[9]. Also other European countries, such as Belgium, 
Cyprus  and  Germany  have  reported  an  increasing 
number of cases since 2007, albeit to a smaller extent 
[2].
The  prevalence  of  Q  fever  among  pregnant  women 
is  unknown.  Recently  published  data  from  the 
Netherlands showed a prevalence of immunoglobulin 
(Ig)M, suggesting recent infection with C. burnetii, in 
3.4%  of  1,646  tested  serum  samples  from  pregnant 
women in Q fever high-risk areas [10]. In a cohort study 
from Canada, 3.8% of parturient women had evidence 
of  previous  exposure  to  C.  burnetii  (presence  of  IgG 
phase  I  and/or  II).  These  women  had,  in  contrast  to 
the  Dutch  seropositive  women  [10],  a  higher  risk  for 
adverse  pregnancy  outcomes,  in  terms  of  premature 
delivery and prior or current neonatal death, compared 
with  seronegative  women  [11].  A  milestone  hospital-
based study from France showed that 81% of the preg-
nant women with untreated Q fever had a miscarriage, 
premature delivery, intrauterine growth restriction or 
foetal death. Furthermore, chronic Q fever occurred in 
50% of the cases, of whom 10% developed C. burnetii 
endocarditis [3]. These figures are alarming, but need 
to be cautiously interpreted as the retrospective design 
covering many years may have led to some overestima-
tion  of  risks.  Certainly,  this  study  together  with  the 
prevalence studies emphasise that C. burnetii infection 
is a potential threat to pregnant women.
Is there a latent or early symptomatic stage?
Up to 90% of infected pregnant women remain asymp-
tomatic [4]. Therefore, early detection, before obstet-
ric  complications  and  maternal  chronic  Q  fever  have 
occurred, enables treatment that may prevent compli-
cations due to C. burnetii infection [3].
Is the natural history of Coxiella burnetii 
infection adequately understood?
C. burnetii is a small gram-negative intracellular living 
bacterium. The main route of transmission is the res-
piratory route, in which alveolar macrophages in the 
lungs are the first cells to be infected [12]. Furthermore, 
the placenta seems to be a target organ since placen-
titis has been described in both animals and humans 
[3,13]. After the primary infection, C. burnetii has the 
ability to induce chronic infections. It is hypothesised 
that, besides the liver, bone, heart valves and mural 
endocardium [14], the uterus could be a site of latent 
infection,  hence  reactivation  during  pregnancy  can 
occur [3,11].
The pathogenesis of obstetric complications following 
infection is not completely understood; immune com-
plexes may cause vasculitis and vascular thrombosis, 
which in turn may lead to the placental insufficiency 
and  subsequent  obstetric  complications  [15].  Also, 
direct transplacental transmission by C. burnetii may 
cause foetal death [16]. Obstetric complications occur 
significantly more often in patients who are infected 
during the first trimester of pregnancy than in those 
infected later [3].
Not  only  have  acute  infections  been  associated  with 
obstetric  complications,  but  also  previous  infections 
seem to increase the risk [11]. There is no good expla-
nation  for  this  association  besides  the  hypothesis 
of intrauterine latency of the infection [11]. In all, the 
natural history of C. burnetii infection among pregnant 
women is not completely understood.
The screening population
Since  the  Q  fever  incidence  largely  varies  between 
regions  (see  for  example  the  situation  in  the 
Netherlands, figure), the population for routine screen-
ing should be limited to pregnant women living in high-
risk Q fever areas. Women living within a five-kilometre 
zone around a dairy goat or dairy sheep farm affected 
by C. burnetii-related abortion waves have the highest 
risk of contracting an infection, however, still 41% of 
the Dutch cases in 2009 lived outside of these areas [8]. 
Whether these cases visited the five-kilometre zones is 
unclear. Therefore, if introduced, routine screening of 
all pregnant women would be advisable in areas with a 
high incidence (e.g. >50/100,000 inhabitants). So, with 
a good surveillance system, the screening population 
can be accurately defined. Screening of specific groups 
at risk, e.g. pregnant women with occupational hazard 
for Q fever or with complicated pregnancies can also 
be considered, but is beyond the scope of this study 
discussing routine screening of a total population.
Similar to other screening programs during pregnancy, 
eligible women have to be counselled about the ben-
efits  and  possible  consequences  of  the  screening 
(i.e. long-term antibiotic treatment and hospital birth 
instead  of  home  birth  in  case  of  an  acute  infection, 
stress  induced  by  awareness  of  infectious  diseases 
during  pregnancy)  to  be  able  to  make  an  informed 
choice about participation.
Is there an agreed policy on whom to treat as patients?
All  phases  of  C.  burnetii  infection  during  pregnancy 
have  been  associated  with  adverse  pregnancy  out-
come.  However,  evidence  for  the  benefits  of  antibi-
otic treatment is only available in patients with acute 
and chronic Q fever [3]. Whether antibiotic treatment 
prevents  complications  in  women  with  asymptomatic 
seropositivity needs to be investigated.23 www.eurosurveillance.org
Is case finding a continuing process 
and not a ’once and for all‘ project?
If introduced, screening for C. burnetii infection should 
be performed during each pregnancy since the infec-
tion can be contracted at any moment and reactivation 
during  pregnancy  of  a  previous  infection  may  occur 
[3,11]. Therefore case finding is a continuing process.
The test and the treatment
Is there a suitable test?
There  are  several  accurate  methods  to  diagnose 
C. burnetii infection, including culture, PCR and serol-
ogy, of which serology is most suitable for screening 
[17].  However,  the  performance  of  these  tests  dur-
ing pregnancy is unknown. In the general population, 
indirect  immunofluorescence  assay  (IFA)  is  the  refer-
ence method [17,18]. Since one of the characteristics 
of C. burnetii is antigenetic phase variation, antibod-
ies against two phases of antigens can be detected. 
All  types  of  antibodies  have  their  own  timeframe  of 
appearance,  therefore  distinguishing  previous,  acute 
and chronic infections is possible [12,18]. As already 
mentioned,  test  characteristics  during  pregnancy  are 
unknown.  From  other  infectious  diseases  we  know 
that false-positive serological results occur quite often 
during  pregnancy  [19].  Furthermore,  with  respect  to 
sensitivity and specificity, there is an ongoing debate 
about which cut-off values to use, especially because 
there  are  many  different  commercial  and  in-house 
methods. In all, more research needs to be performed 
with  respect  to  serological  screening  for  C.  burnetii 
during  pregnancy  before  routine  screening  can  be 
implemented.
Is the test acceptable to the population?
Acceptance of the test can be expected since only one 
blood sample is necessary, which can be obtained by 
venepuncture  combined  with  the  screening  for  other 
infectious diseases around 12 weeks of pregnancy. An 
advantage of testing in the first trimester is the pos-
sibility of early counselling and treatment during the 
most vulnerable phase of pregnancy [3]. However, with 
early screening, infections later in pregnancy would be 
missed.  Timing  of  the  screening  needs  to  be  further 
investigated, also taking into account a seasonal varia-
tion in C. burnetii spreading [9].
Is there an accepted treatment for 
patients with recognised disease?
First choice treatment for Q fever among the general 
population is a 14-day antibiotic treatment with doxy-
cycline or fluoroquinolone [12]. However, both agents 
are contraindicated during pregnancy. Long-term treat-
ment with cotrimoxazole has been suggested to be the 
treatment  of  choice  during  pregnancy  [3].  However, 
use of cotrimoxazole during pregnancy has not been 
fully investigated yet. Pharmacological activity of this 
drug could cause folic acid depletion in the foetus [20]. 
Furthermore,  neonatal  hyperbilirubinemia  has  been 
described when used prior to delivery. However, these 
risks turned out to be small in large groups of pregnant 
women with HIV who received prophylactic cotrimox-
azole therapy during pregnancy [21]. In all, more evi-
dence for the best treatment option during pregnancy 
is needed.
Are there facilities for diagnosis 
and treatment available?
Since  screening  for  other  infectious  diseases  dur-
ing pregnancy is already routinely performed, adding 
C. burnetii screening will be relatively straightforward. 
In the Netherlands, as in other Western countries, sev-
eral laboratories have facilities to perform C. burnetii 
serology.  Quality  assessments  should  be  performed 
on  a  regular  basis.  Treatment  and  follow-up  of  posi-
tively screened women should be performed by obste-
tricians,  infectious  disease  specialists  and  medical 
microbiologist, who should receive additional training 
on diagnostics and treatment of C. burnetii infection 
during pregnancy.
The costs
Are the costs of case finding economically balanced in 
relation to possible expenditure on medical care as a 
whole?
Figure
Human Q fever incidence per 100,000 inhabitants per 
municipality in the Netherlands, 1 January–12 August 
2009
Incidences are based on symptomatic (fever, pneumonia and/or 
hepatitis), laboratory-confirmed Q fever cases. 
Source: National Institute for Public Health and the Environment 
(RIVM).
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Outcomes of cost-effectiveness models are not avail-
able yet and input data are required. Screening with IFA 
and antibiotic treatment are relatively cheap, though 
referral  for  treatment  and  hospital  birth  may  induce 
high costs since around 25% of the deliveries in the 
Netherlands normally take place at home [22].
The adapted Wilson and Jungner criteria, addressed in 
this study are summarised in the table.
Conclusion
According to the adapted Wilson and Jungner criteria 
(Table), the currently available evidence is insufficient 
to promote routine screening for C. burnetii infection 
during pregnancy in high-risk Q fever areas. Because 
of potential bias in the studies reported so far, there 
is  too  much  uncertainty  about  the  consequences  of 
untreated C. burnetii infection during pregnancy. There 
is also no consensus about the screening method and 
treatment. Furthermore, Q fever incidence rates highly 
affect  the  effectiveness  of  screening.  Therefore  the 
candidate populations for screening are not static and 
should be identified based on epidemiological criteria. 
Finally, besides screening, there are other methods to 
prevent C. burnetii related complications, for example 
human vaccination [23]. Overall, more evidence about 
the effectiveness of a C. burnetii screening program, 
in  addition  to  other  Q  fever  prevention  and  control 
measures taken by the European countries, is needed 
before this infection will become a candidate for rou-
tine screening during pregnancy. 
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